美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

減肥藥

1,492.17

+31.152.13%

漲家數：5

跌家數：2

平家數：- -

市盈率：- -

高：1,493.70

開：1,460.44

低：1,460.44

收：1,461.02

資料載入中...

總覽新聞資訊

Viking Therapeutics, Inc.盤中異動股價大漲5.03%

Altimmune, Inc.盤中異動早盤股價大漲6.06%

印度工廠進口受限，製藥商 Viatris 預計 2025 年業績疲軟

諾維信縮減 COVID 疫苗支出，季度虧損減少

一代分子POCT明星落幕！

新藥開發難，輝瑞、渤健接連削減研發管線！

中国制药网

康方生物合作伙伴summit與輝瑞探究聯合療法，賦能AK112全球臨牀

碩迪生物盤中異動大幅下跌5.14%報20.01美元

【歐股“十一羅漢”｜阿斯麥和LVMH集團收漲超2%，諾和諾德跌超2%】週三，阿斯麥控股荷蘭阿姆斯特丹股價收漲2.39%，報714.50歐元。諾和諾德哥本哈根股價收跌2.16%，報642.80。LVMH集團漲2.35%，德國思愛普Sap漲1.03%，歐萊雅、賽諾菲、羅氏製藥漲0.81%-0.20%。阿斯利康則收跌0.42%，葛蘭素史克和雀巢至多跌2.16%，諾華製藥跌3.85%。

安進盤中異動股價大跌3.00%報306.15美元

禮來下調美國市場減肥藥價格，中國市場是否跟進

FDA官員加入輝瑞擔任高管，職業凱旋門？

Summit“滯銷”

AI獲醫藥巨頭認可！諾和諾德：AI終於足夠可靠，可以生成敏感文件

华尔街见闻

定價高達350萬美元的基因療法，上市一年未有銷售！輝瑞宣佈撤退

中国制药网

市場風雲突變！誰能穩坐“減肥藥王”寶座？

Ofweek光电信息网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4599/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"減肥藥","latestPrice":1492.1732,"timestamp":1741208399999,"preClose":1461.0245,"halted":0,"volume":58200771,"delay":0,"changeRate":0.02132,"change":31.148682,"pbRate":11.780703,"amount":5513579718.723701,"amplitude":0.02276,"prevYearClose":1305.0607,"fiveDayClose":1473.773,"twentyDayClose":1354.5123,"turnoverRate":0.005514,"marketCap":1606807813984,"floatMarketCap":1490733575264,"peRate":41.703544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1493.6967,"amplitude":0.02276,"preClose":1461.0245,"low":1460.4442,"pbRate":"11.780703","latestPrice":1492.1732,"volume":58200771,"delay":0,"open":1460.4442,"prevYearClose":1305.0607,"prevWeekClose":1482.1702,"prevMonthClose":1482.1702,"prevQuarterClose":1305.0607,"fiveDayClose":1473.773,"twentyDayClose":1354.5123,"sixtyDayClose":1441.3252,"secType":"PLATE","market":"US","turnoverRate":0.005514,"peRate":41.703544,"marketCap":1606807813984,"floatMarketCap":1490733575264,"timestamp":1741208399999,"nameCN":"減肥藥"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":5,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:16,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514038900","title":"Viking Therapeutics, Inc.盤中異動 股價大漲5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514038900?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 23:23","pubTimestamp":1740669804,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时23分，Viking Therapeutics, Inc.股票出现异动，股价大幅上涨5.03%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.14%。其相关个股中，Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Editas Medicine, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为884.66%、177.60%、104.83%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Quoin Pharmaceuticals Ltd，振幅分别为74.16%、43.51%、34.80%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LENZ","BK4599","BK4139","VKTX","BK4588"],"gpt_icon":0},{"id":"2514385796","title":"Altimmune, Inc.盤中異動 早盤股價大漲6.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514385796?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 22:35","pubTimestamp":1740666911,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时35分，Altimmune, Inc.股票出现波动，股价快速上涨6.06%。截至发稿，该股报6.30美元/股，成交量22.7561万股，换手率0.32%，振幅4.55%。Altimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Alector, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为430.02%、92.85%、67.12%，振幅较大的相关个股有Channel Therapeutics Corporation、Quoin Pharmaceuticals Ltd、Neurosense Therapeutics Ltd C/Wts 10/11/2026 ，振幅分别为16.42%、15.14%、14.83%。Altimmune, Inc.公司简介：Altimmune Inc 从事开发治疗肥胖症和肝病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223511abdf6f9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223511abdf6f9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1878469433.USD","BK4599","ALT","BK4139"],"gpt_icon":0},{"id":"2514780287","title":"印度工廠進口受限，製藥商 Viatris 預計 2025 年業績疲軟","url":"https://stock-news.laohu8.com/highlight/detail?id=2514780287","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514780287?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 21:18","pubTimestamp":1740662318,"startTime":"0","endTime":"0","summary":"Viatris 的股票在盘前交易中下跌了 14.6%。Viatris于2024年12月23日披露，由于违反联邦要求，美国食品和药物管理局 已限制  从其位于印度印多尔 的工厂进口 11种产品。根据 LSEG 编制的数据，总部位于宾夕法尼亚州卡农斯堡的Viatris 预计 2025 年收入在 135 亿美元 至 140  亿美元之间，低于分析师预计的 142.7 亿美元。由于担心产品短缺，美国食品和药物管理局已允许 Viatris 的四种产品例外，但具体产品尚未披露。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3T3PI18P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999011175.SGD","LU0868494617.USD","LU0306806265.USD","SG9999001176.USD","LU0985481810.HKD","LU1066053197.SGD","SG9999002232.USD","IE00B19Z3581.USD","LU1894683348.USD","VTRS","LU1839511570.USD","LU0289739699.SGD","BK4581","SG9999003800.SGD","SG9999013999.USD","SGXZ57979304.SGD","LU2087621335.USD","IE00BBT3K403.USD","LU0225771236.USD","BK4585","LU1883839398.USD","LU0456855351.SGD","BK4583","BK4568","LU0306807586.USD","LU0058720904.USD","SG9999001176.SGD","BK4007","IE000M9KFDE8.USD","LU1066051498.USD","LU0321505439.SGD","LU0225284248.USD","SG9999002224.SGD","BK4588","BK4592","IE00BLSP4452.SGD","LU0170899867.USD","LU0122379950.USD","LU0234572021.USD","LU1894683264.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","IE00BLSP4239.USD","BK4599","BK4550","BK4534","LU1057294990.SGD","BK4533"],"gpt_icon":1},{"id":"2514048588","title":"諾維信縮減 COVID 疫苗支出，季度虧損減少","url":"https://stock-news.laohu8.com/highlight/detail?id=2514048588","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514048588?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 21:02","pubTimestamp":1740661358,"startTime":"0","endTime":"0","summary":"路透社2月27日 - 周四，NovavaxNVAX.O第四季度亏损收窄，原因是其唯一上市产品COVID-19疫苗的销售和管理费用减少。Novavax报告称，COVID疫苗的季度销售额为4980万美元，同比下降了80.2%。该公司将依靠与赛诺菲的交易和在研疫苗带来的收入，包括处于临床前阶段的试验性 COVID 流感复合疫苗和禽流感疫苗。诺瓦维克斯表示，它有资格从赛诺菲的销售额中获得百分之十几到二十几的特许权使用费，以及与 COVID 流感组合产品相关的 3.5 亿美元的商业投放费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3T3PI17I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU0058720904.USD","BK4588","BK4551","IE00BBT3K403.USD","SG9999002224.SGD","BK4501","LU1066053197.SGD","BK4568","LU0985481810.HKD","LU0306806265.USD","BK4533","LU0225284248.USD","LU0234572021.USD","BK4534","BK4581","LU0306807586.USD","IE00BLSP4452.SGD","IE00B19Z3B42.SGD","LU0122379950.USD","LU0170899867.USD","BK4007","NVAX","BK4139","IE000M9KFDE8.USD","BK4585","SG9999003800.SGD","IE00BLSP4239.USD","SGXZ57979304.SGD","LU1894683348.USD","LU0289739699.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4592","SG9999013999.USD","LU1023059063.AUD","LU0321505868.SGD","BK4547","BK4548","LU1883839398.USD","SG9999001176.USD","LU0456855351.SGD","LU0868494617.USD","BK4550","LU1066051498.USD","LU0225771236.USD","BK4532","LU1894683264.USD"],"gpt_icon":1},{"id":"2514388535","title":"一代分子POCT明星落幕！","url":"https://stock-news.laohu8.com/highlight/detail?id=2514388535","media":"IVD资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514388535?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:50","pubTimestamp":1740649837,"startTime":"0","endTime":"0","summary":"Lucira Health从破产到收购2023年2月22日，美国明星分子诊断公司Lucira Health因财务压力向特拉华州破产法院申请破产保护。Lucira的破产反映POCT领域竞争激烈，技术门槛与商业化能力缺一不可。Lucira的分子POCT虽具创新性，但成本与供应链问题导致盈利困难；新冠检测退潮后，企业转向多元检测场景，并拓展基层医疗与家庭市场，但未能成功突破。辉瑞看中Lucira的分子POCT技术及FDA获批产品线，认为其资源可推动后续商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227220810abdf6864&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227220810abdf6864&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3581.USD","IE00BLSP4239.USD","SG9999002224.SGD","LU0170899867.USD","BK4588","LU1894683264.USD","LU1023059063.AUD","SG9999011175.SGD","LU1883839398.USD","BK4533","LU0456855351.SGD","LU0225284248.USD","LU0234572021.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0321505439.SGD","POCT","SG9999001176.SGD","BK4592","IE0002270589.USD","LU1066051498.USD","LU1894683348.USD","SG9999002232.USD","SG9999003800.SGD","BK4007","BK4585","LU1057294990.SGD","LU0225771236.USD","LU0321505868.SGD","PFE","BK4599","BK4534","SG9999013999.USD","BK4568","IE00B19Z3B42.SGD","LU0868494617.USD","LU0058720904.USD","IE00BBT3K403.USD","LU0985481810.HKD","BK4550","LU0306807586.USD","SGXZ57979304.SGD","LU0289739699.SGD","LU0306806265.USD","LU0122379950.USD","SG9999001176.USD","IE000M9KFDE8.USD","BK4581"],"gpt_icon":1},{"id":"2514842990","title":"新藥開發難，輝瑞、渤健接連削減研發管線！","url":"https://stock-news.laohu8.com/highlight/detail?id=2514842990","media":"中国制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514842990?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 14:04","pubTimestamp":1740636261,"startTime":"0","endTime":"0","summary":"近期，辉瑞、渤健、礼来等跨国制药巨头就已相继终止了多款高价新药的开发。近日，有报道称，辉瑞在宣布将终止B型血友病基因疗法Beqvez的开发和商业化。据悉，放弃Beqvez后，辉瑞打算将其资源集中在其认为将对患者产生重大影响的治疗方法上，例如近期获得批准的一种血友病A新药Hympavzi上。业内表示，这些药企终止药物开发的案例，反映出药企在新药开发和商业化上一直都在面临重大挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227141109a255d6e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227141109a255d6e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999011175.SGD","LU1894683348.USD","BK4007","BK4534","LU0234572021.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4585","LU1066051498.USD","LU1894683264.USD","LU0058720904.USD","LU0321505439.SGD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","BK4533","BK4568","BK4581","LU1057294990.SGD","BK4550","PFE","SG9999002232.USD","SG9999001176.SGD","LU1023059063.AUD","SG9999001176.USD","LU1066053197.SGD","LU0289739699.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","BK4592","LU0225771236.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999002224.SGD","IE00BLSP4239.USD","BK4588","LU0122379950.USD","IE00BLSP4452.SGD","LU0170899867.USD","LU0225284248.USD","LU0306807586.USD","LU0321505868.SGD","IE0002270589.USD","BK4599","LU1883839398.USD","IE00B19Z3B42.SGD","LU0985481810.HKD"],"gpt_icon":0},{"id":"2514818809","title":"康方生物合作伙伴summit與輝瑞探究聯合療法，賦能AK112全球臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2514818809","media":"中信建投","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514818809?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 08:16","pubTimestamp":1740615369,"startTime":"0","endTime":"0","summary":"事件康方生物/Su mmit AK112与辉瑞A DC探索联合疗法2025年2月24日，康方全球合作伙伴Su mmit Therapeutics宣布与辉瑞开展临床合作，以评估PD-1/VEGF双特异性抗体Ivonescimab与辉瑞的多种抗体偶联药物联合用于多种实体瘤的疗效和安全性。简评一、合作伙伴Su mmit与辉瑞达成合作，赋能AK112全球临床研发2025年2月24日，Su mmit Therapeutics公布2024年财报，披露了研发管线最新进展，同时宣布与辉瑞达成临床合作，开展PD-1/VEGF+A DC联合治疗实体瘤的临床探索。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227084028a2557e18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227084028a2557e18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0122379950.USD","SG9999003800.SGD","LU0985481810.HKD","LU0170899867.USD","SG9999013999.USD","LU0306807586.USD","LU1894683264.USD","LU0306806265.USD","LU1883839398.USD","BK4585","IE0002270589.USD","BK4550","SG9999001176.SGD","BK4588","IE00B19Z3B42.SGD","SG9999002224.SGD","LU1894683348.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","LU0234572021.USD","IE000M9KFDE8.USD","LU1057294990.SGD","IE00BBT3K403.USD","LU0225284248.USD","BK4534","IE00BLSP4452.SGD","LU0321505868.SGD","LU1066053197.SGD","PFE","BK4581","SG9999011175.SGD","LU1023059063.AUD","LU0058720904.USD","SG9999001176.USD","LU0225771236.USD","SGXZ57979304.SGD","BK4533","BK4599","BK4007","LU0321505439.SGD","SG9999002232.USD","LU0289739699.SGD","BK4568","BK4592","LU1066051498.USD","LU0868494617.USD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2514861634","title":"碩迪生物盤中異動 大幅下跌5.14%報20.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514861634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514861634?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 03:10","pubTimestamp":1740597043,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时10分，硕迪生物股票出现波动，股价大幅跳水5.14%。截至发稿，该股报20.01美元/股，成交量29.5875万股，换手率0.52%，振幅6.99%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-34.26百万美元，每股收益-0.60美元，毛利-267175.50美元，市盈率-9.26倍。机构评级方面，在所有11家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031044abde29f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031044abde29f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2514695998","title":"【歐股“十一羅漢”｜阿斯麥和LVMH集團收漲超2%，諾和諾德跌超2%】週三，阿斯麥控股荷蘭阿姆斯特丹股價收漲2.39%，報714.50歐元。諾和諾德哥本哈根股價收跌2.16%，報642.80。LVMH集團漲2.35%，德國思愛普Sap漲1.03%，歐萊雅、賽諾菲、羅氏製藥漲0.81%-0.20%。阿斯利康則收跌0.42%，葛蘭素史克和雀巢至多跌2.16%，諾華製藥跌3.85%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514695998","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514695998?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 02:33","pubTimestamp":1740594799,"startTime":"0","endTime":"0","summary":"周三，阿斯麦控股荷兰阿姆斯特丹股价收涨2.39%，报714.50欧元。诺和诺德哥本哈根股价收跌2.16%，报642.80。LVMH集团涨2.35%，德国思爱普Sap涨1.03%，欧莱雅、赛诺菲、罗氏制药涨0.81%-0.20%。阿斯利康则收跌0.42%，葛兰素史克和雀巢至多跌2.16%，诺华制药跌3.85%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27023348414142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NSRGY","LU2417539215.USD","LU2456880835.USD","IE0002141913.USD","IE00BZ1G4Q59.USD","BK4543","IE00BD6J9T35.USD","LU1093756168.USD","LRLCY","IE0004445239.USD","BK4147","NVO","IE00BJT1NW94.SGD","LU2462157665.USD","BK4585","IE00BFTCPJ56.SGD","IE00BKVL7J92.USD","ASML","BK1191","LU1734074674.USD","BK4568","IE0009355771.USD","LU1093756325.SGD","LU2236285917.USD","01477","BK1574","BK4007","LU0823434583.USD","LU0109394709.USD","BK4212","AZN","NVS","LU0320765992.SGD","BK4183","GSK","BK4588","03165","LU0097036916.USD","BK4532","LU0154236417.USD","LU0823434740.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU2063271972.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","LU1829250122.USD","LU0889565916.HKD","BK4599","GSK.UK"],"gpt_icon":0},{"id":"2514286547","title":"安進盤中異動 股價大跌3.00%報306.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514286547","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514286547?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 01:56","pubTimestamp":1740592595,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日01时56分，安进股票出现波动，股价大幅跳水3.00%。截至发稿，该股报306.15美元/股，成交量127.737万股，换手率0.24%，振幅2.34%。最近的财报数据显示，该股实现营业收入332.32亿美元，净利润40.90亿美元，每股收益7.62美元，毛利213.33亿美元，市盈率40.51倍。安进股票所在的制药行业中，整体跌幅为0.22%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227015635963175b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227015635963175b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU2112291526.USD","AMGN","BK4534","BK4533","LU1571399168.USD","LU0109394709.USD","LU1057294990.SGD","BK4588","LU2242652126.USD","LU1023059063.AUD","LU0122379950.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4566","IE00BJJMRZ35.SGD","SG9999001440.SGD","BK4139","LU0289739699.SGD","BK4599","LU0868494617.USD","LU1983299246.USD","IE0009355771.USD","BK4581","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU2242646821.SGD","LU0058720904.USD","LU0889565916.HKD","LU1061106388.HKD","BK4585"],"gpt_icon":0},{"id":"2514887118","title":"禮來下調美國市場減肥藥價格，中國市場是否跟進","url":"https://stock-news.laohu8.com/highlight/detail?id=2514887118","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514887118?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 18:07","pubTimestamp":1740564440,"startTime":"0","endTime":"0","summary":"当地时间2月25日，礼来美国市场宣布，下调减肥药Zepbound小瓶装的价格。公开资料显示，此次降价后，这两个剂量的药物月费用均减少50美元。替尔泊肽已进入中国市场销售。今年1月2日，礼来中国宣布穆峰达正式在中国上市，同时覆盖降糖以及减肥两项适应证。在全球市场，礼来的替尔泊肽直面与诺和诺德的司美格鲁肽竞争，后者属于GLP-1R单靶点药物，但上市时间更早。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226180819abddaa51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226180819abddaa51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LLY","LU1983299246.USD","SG9999013999.USD","LU0079474960.USD","IE00B4R5TH58.HKD","LU2491050071.SGD","LU1093756168.USD","LU1868836757.USD","SG9999014880.SGD","LU1551013425.SGD","LU0354030438.USD","LU1267930730.SGD","IE00BJJMRZ35.SGD","LU0672654240.SGD","LU0882574055.USD","LU2324357040.USD","BK4599","LU0058720904.USD","LU2089984988.USD","SGXZ81514606.USD","LU1720051108.HKD","LU0471298694.HKD","LU0354030511.USD","LU1868836591.USD","YINN","LU1064131342.USD","LU1868837300.USD","SGXZ31699556.SGD","LU0061475181.USD","LU1868836914.USD","BK4581","LU0943347566.SGD","LU2264538146.SGD","LU2237443622.USD","LU2211815571.USD","SG9999014914.USD","LU2491050154.USD","SG9999018865.SGD","LU0417517546.SGD","LU1280957306.USD","LU0096364046.USD","SG9999014898.SGD","LU0823416689.USD","LU0106261372.USD","LU0238689110.USD","IE00B1BXHZ80.USD","LU2360106947.USD","LU1989771016.USD","SG9999018857.SGD","LU0689472784.USD"],"gpt_icon":1},{"id":"2514835871","title":"FDA官員加入輝瑞擔任高管，職業凱旋門？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514835871","media":"医药财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514835871?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 15:43","pubTimestamp":1740555811,"startTime":"0","endTime":"0","summary":"据悉，Patrizia Cavazzoni于今年1月离职FDA，她将领导辉瑞集团的监管、安全和医疗业务。然而，Patrizia Cavazzoni加入辉瑞担任首席医疗官的事件，可能引发多方面的讨论和影响，需从以下角度分析：1.职业旋转门的争议潜在利益冲突：Cavazzoni从监管机构转至药企，可能引发对其利用FDA内部经验或人脉的质疑。公众可能担忧监管机构与企业间的“旋转门”现象削弱监管独立性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226190634a254c14f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226190634a254c14f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BBT3K403.USD","SG9999011175.SGD","BK4534","LU0225771236.USD","LU0289739699.SGD","PFE","BK4592","LU0306807586.USD","LU0306806265.USD","BK4599","LU0456855351.SGD","LU1066053197.SGD","BK4007","LU0234572021.USD","SG9999001176.USD","BK4588","SG9999002232.USD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","LU1894683348.USD","LU0122379950.USD","SG9999003800.SGD","LU0321505439.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","BK4550","BK4585","BK4568","IE00BLSP4239.USD","IE00B19Z3581.USD","LU0321505868.SGD","SG9999002224.SGD","LU0058720904.USD","IE00BLSP4452.SGD","LU0868494617.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","LU0985481810.HKD","SG9999013999.USD","LU0225284248.USD","LU1894683264.USD","BK4533","BK4581","IE000M9KFDE8.USD","IE0002270589.USD"],"gpt_icon":1},{"id":"2514005348","title":"Summit“滯銷”","url":"https://stock-news.laohu8.com/highlight/detail?id=2514005348","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514005348?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 14:29","pubTimestamp":1740551372,"startTime":"0","endTime":"0","summary":"Summit的潜在买家，范围持续缩窄。2月24日，Summit宣布与辉瑞达成临床试验合作，共同评估PD-1/VEGF双抗AK112与辉瑞多个ADC联合用于多种实体瘤的疗效和安全性。根据合作条款，辉瑞将负责临床试验的开展和费用，Summit则供药，双方各自保留其产品的相关权利。在乐观者看来，这是辉瑞盯上了Summit。合作消息发布后，Summit股价应声大跌14.83%。当然，Summit“滞销”并非说AK112前景不好。Summit股价大跌，但康方生物今日股价涨幅近5%。此次与Summit牵手，“暧昧”程度不用多说。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/251700","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0321505439.SGD","LU1585245621.USD","IE000M9KFDE8.USD","SG9999014542.SGD","LU0203345920.USD","LU0321505868.SGD","LU0289739699.SGD","LU0965509283.SGD","LU1989772840.SGD","LU2023250504.SGD","LU0985481810.HKD","LU1989772923.USD","LU0058720904.USD","SG9999015341.SGD","BK4533","LU1023059063.AUD","LU1093756168.USD","IE00BJJMRZ35.SGD","LU1699723380.USD","LU1989771016.USD","SG9999015358.SGD","LU1934455194.USD","LU0234572021.USD","SG9999001176.SGD","BK4588","LU2468319806.SGD","LU0211331839.USD","IE0009355771.USD","IE00B2B36J28.USD","LU1894683264.USD","IE00BBT3K403.USD","LU0320765489.SGD","IE00BSNM7G36.USD","BK4599","SG9999002224.SGD","SG9999001440.SGD","SG9999013999.USD","LU0965508806.USD","BK4585","BK4550","LU0265550359.USD","IE00B19Z3B42.SGD","LU1571399168.USD","LU1929549753.HKD","LU1061106388.HKD","IE00BN8TJ469.HKD","LU1066051225.USD","LU0238689110.USD"],"gpt_icon":1},{"id":"2514794330","title":"AI獲醫藥巨頭認可！諾和諾德：AI終於足夠可靠，可以生成敏感文件","url":"https://stock-news.laohu8.com/highlight/detail?id=2514794330","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514794330?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 11:43","pubTimestamp":1740541419,"startTime":"0","endTime":"0","summary":"目前，诺和诺德已经开始使用Claude起草临床研究报告，每份可长达数百页。相关负责人透露，AI工具的使用极大缩短了文件起草时间，从约15周减少到不到10分钟，且公司每年在Claude上的支出不到一名撰稿人的薪资。","market":"us","thumbnail":"https://static.tigerbbs.com/683468f057f519a90154e567b0fb2faf","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/683468f057f519a90154e567b0fb2faf"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3741894","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3741894","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AI获医药巨头认可！诺和诺德：AI终于足够可靠，可以生成敏感文件","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BK4588","LU1093756168.USD","BK4532","LU0154236417.USD","NVO","BK1574","BK4007","BK4585","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK1161","BK1515","BK4599","LU1093756325.SGD"],"gpt_icon":1},{"id":"2514075929","title":"定價高達350萬美元的基因療法，上市一年未有銷售！輝瑞宣佈撤退","url":"https://stock-news.laohu8.com/highlight/detail?id=2514075929","media":"中国制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514075929?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 10:40","pubTimestamp":1740537620,"startTime":"0","endTime":"0","summary":"近日，制药头部辉瑞做出一项重大决策，宣布停止 B 型血友病基因疗法 Beqvez 的研发和商业化进程。值得一提的是Beqvez 在 2024 年 4 月才刚刚获得 FDA 批准上市，定价高达 350 万美元，但是一年时间过去，辉瑞便决定终止了该药物的开发和商业化。这一系列动作表明，辉瑞正在逐步退出细胞基因疗法领域。Biomarin 公司的 A 型血友病基因疗法 RocTavian 同样销售缓慢，2023 年 6 月获 FDA 批准上市，定价 2900 万美元，2024 年销售额仅 2600 万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226110458abdd316c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226110458abdd316c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3581.USD","IE00BLSP4239.USD","SG9999002224.SGD","LU0170899867.USD","BK4588","LU1894683264.USD","LU1023059063.AUD","SG9999011175.SGD","LU1883839398.USD","BK4533","LU0456855351.SGD","LU0225284248.USD","LU0234572021.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4592","IE0002270589.USD","LU1066051498.USD","LU1894683348.USD","SG9999002232.USD","SG9999003800.SGD","BK4007","BK4585","LU1057294990.SGD","LU0225771236.USD","LU0321505868.SGD","PFE","BK4599","BK4534","SG9999013999.USD","BK4568","IE00B19Z3B42.SGD","LU0868494617.USD","LU0058720904.USD","IE00BBT3K403.USD","LU0985481810.HKD","BK4550","LU0306807586.USD","SGXZ57979304.SGD","LU0289739699.SGD","LU0306806265.USD","LU0122379950.USD","SG9999001176.USD","IE000M9KFDE8.USD","BK4581"],"gpt_icon":1},{"id":"2514020435","title":"市場風雲突變！ 誰能穩坐“減肥藥王”寶座？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514020435","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514020435?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 09:54","pubTimestamp":1740534840,"startTime":"0","endTime":"0","summary":"如今，市场悄然发生变化。同时，礼来的减肥药在国内开售，区域性的销售法规出台。今年2月，诺和诺德直接将亨利医药及黄振华告上法庭，指控其涉嫌欺诈。至于交易完成后的转移资产行为，目前黄振华方面尚未出面解释。目前，诺和诺德已向新加坡法院申请，向黄振华及其企业合计索赔8.3亿美元，并要求全球范围内冻结相关资产。目前，法院仍未最终裁定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022609562996308237&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022609562996308237&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4599","BK4585","IE00BKVL7J92.USD","LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","BK4532","BK4007"],"gpt_icon":1}],"pageSize":16,"totalPage":7,"pageCount":3,"totalSize":109}]}}